TrianglePUBLICATIONS · 36395435
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2023 Feb 10
- First author
- Hillmen P
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Hillmen P
- type
- Author
- name
- Eichhorst B
- type
- Author
- name
- Brown JR
- type
- Author
- name
- Lamanna N
- type
- Author
- name
- O'Brien SM
- type
- Author
- name
- Tam CS
- type
- Author
- name
- Qiu L
- type
- Author
- name
- Kazmierczak M
- type
- Author
- name
- Zhou K
- type
- Author
- name
- Šimkovič M
- type
- Author
- name
- Mayer J
- type
- Author
- name
- Gillespie-Twardy A
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Hillmen P
- type
- Author
- name
- Eichhorst B
- type
- Author
- name
- Brown JR
- type
- Author
- name
- Lamanna N
- type
- Author
- name
- O'Brien SM
- type
- Author
- name
- Tam CS
- type
- Author
- name
- Qiu L
- type
- Author
- name
- Kazmierczak M
- type
- Author
- name
- Zhou K
- type
- Author
- name
- Šimkovič M
- type
- Author
- name
- Mayer J
- type
- Author
- name
- Gillespie-Twardy A
- type
- Author
- bibliography ids
- nci-bib-033ef37a43b9e6b0dd2bba81
- book metadata
- content sha256
- b33609ddda84d9b4534f8abf8edccd7253ff77d2fdc047876110a0b894a21e37
- document type
- citation
- dois
- 10.1200/JCO.22.00510
- electronic publication date
- display
- 2022 Nov 17
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36395435
- immutable id
- pubmed:36395435@b33609ddda84d9b4534f8abf8edccd7253ff77d2fdc047876110a0b894a21e37
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 5
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 1035-1045
- volume
- 41
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36395435
- provenance
- batch id
- d370e99271168e8a8a13
- provider
- NCBI PubMed ESummary
- record sha256
- 908fed6ed7b2d75105f652d7c561cf3898b58d952071ee424ec784facec3fc97
- response sha256
- f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
- retrieved at
- 2026-09-09T23:48:13.005737+00:00
- publication date
- display
- 2023 Feb 10
- precision
- day
- year
- 2023
- publication types
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Preserved source evidence · Not medical advice